New-onset nonarteritic anterior ischemic optic neuropathy and initiators of semaglutide in US veterans with type 2 diabetes

About The Study: In this nationwide cohort of U.S. veterans with type 2 diabetes, semaglutide initiators had a 2-fold nonarteritic anterior ischemic optic neuropathy (NAION) risk than sodium-glucose cotransporter-2 inhibitor initiators, while the absolute risk was low. Clinicians and patients should be counseled on the rare but evident increased risk of NAION after semaglutide initiation. 

Corresponding Author: To contact the corresponding author, Jennifer S. Lee, MD, PhD, email jennifer.lee23@va.gov.

To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/

(doi:10.1001/jamaophthalmol.2025.6262)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaophthalmology/fullarticle/10.1001/jamaophthalmol.2025.6262?guestAccessKey=920a1cd3-919a-4c41-b810-969b792e9550&utm_source=for_the_media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=021226

END